BRCA1 and ovarian carcinoma: The armamentarium of drugs available for ovarian carcinoma treatment is quite poor, although it has been recently enriched by the approval of inhibitors of Poly-ADP ribose polymerase (PARP) both for BRCA1 and BCRA2 mutant cancers as well as for the maintenance therapy of non-mutant platinum-sensitive recurrent ovarian cancer 3.